3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[4-(2-benzoyloxyethyl)benzyl]pyridine | 479481-48-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[4-(2-benzoyloxyethyl)benzyl]pyridine
• 英文别名: 3-(2,3,4,6-tetra-O-acetyl-beta-D-gluco-pyranosyloxy)-4-[4-(2-benzoyloxyethyl)benzyl]pyridine；2-[4-[[3-[(2S,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxypyridin-4-yl]methyl]phenyl]ethyl benzoate
• CAS: 479481-48-6
• 化学式: C₃₅H₃₇NO₁₂
• 分子量: 663.678
• InChiKey: NEMQJPSOYRHOLO-ZXRSUHRQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  48
• 可旋转键数：
  18
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  163
• 氢给体数：
  0
• 氢受体数：
  13

反应信息

• 作为反应物：
  描述：

  3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)-4-[4-(2-benzoyloxyethyl)benzyl]pyridine 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 23.0h， 生成 3-(β-D-glucopyranosyloxy)-4-[4-(2-hydroxyethyl)benzyl]pyridine
  参考文献：
  名称：

  EP1405859

  摘要：

  公开号：

文献信息

• Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor
  申请人：Nishimura Toshihiro

  公开号：US20050049203A1

  公开（公告）日：2005-03-03

  The present invention provides nitrogen-containing heterocyclic derivatives represented by the general formula: wherein X 1 and X 3 independently represent N or CH; X 2 represents N or CR 2 ; X 4 represents N or CR 3 ; and with the proviso that one or two of X 1 , X 2 , X 3 and X 4 represent N; R 1 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted(lower alkoxy) group, a lower alkoxy(lower alkoxy) -substituted (lower alkyl) group, a cyclic lower alkyl group, a halo(lower alkyl) group or a group represented by the general formula: HO-A—wherein A represents a lower alkylene group, a lower alkyleneoxy group or a lower alkylenethio group; R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, a cyclic lower alkyl group, a lower alkoxy group, an amino group, a (lower acyl)amino group, a mono(lower alkyl)amino group or a di(lower alkyl)amino group; and R 3 represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, or prodrugs thereof which are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutical compositions comprising the same, and pharmaceutical uses and production intermediates thereof.

  本发明提供了一种以通式表示的含氮杂环衍生物： 其中，X1和X3独立地表示N或CH；X2表示N或CR2；X4表示N或CR3；并且假定X1、X2、X3和X4中的一个或两个表示N；R1表示氢原子、卤素原子、低碳基、低烷氧基、低硫代烷基、低烷氧基取代的（低烷基）基团、低烷氧基取代的（低烷氧基）基团、低烷氧基（低烷氧基）取代的（低烷基）基团、环状低烷基、卤素（低烷基）基团或由通式HO-A-表示的基团，其中A表示低碳亚烷基、低碳亚烷氧基或低碳亚烷硫基；R2表示氢原子、卤素原子、低碳基、环状低碳基、低烷氧基、氨基、（低酰基）氨基、单（低烷基）氨基或双（低烷基）氨基；R3表示氢原子或低碳基，或其药学上可接受的盐，或其前药，其作为预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症的药剂，包括这些药剂的制剂和制备中间体。
• Nitrogenous heterocyclic derivatives, medicinal compositions containing the same, medicinal uses thereof, and intermediates therefor
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US07271153B2

  公开（公告）日：2007-09-18

  The present invention provides nitrogen-containing heterocyclic derivatives represented by the general formula: wherein X1 and X3 independently represent N or CH; X2 represents N or CR2; X4 represents N or CR3; and with the proviso that one or two of X1, X2, X3 and X4 represent N; R1 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group, a lower alkoxy(lower alkoxy)-substituted (lower alkyl) group, a cyclic lower alkyl group, a halo(lower alkyl) group or a group represented by the general formula: HO-A- wherein A represents a lower alkylene group, a lower alkyleneoxy group or a lower alkylenethio group; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group, a cyclic lower alkyl group, a lower alkoxy group, an amino group, a (lower acyl)amino group, a mono(lower alkyl)amino group or a di(lower alkyl)amino group; and R3 represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, or prodrugs thereof which are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutical compositions comprising the same, and pharmaceutical uses and production intermediates thereof.

  本发明提供了一种由通式表示的含氮杂环衍生物： 其中X1和X3分别独立地表示N或CH；X2表示N或CR2；X4表示N或CR3；并且在X1、X2、X3和X4中的一个或两个表示N；R1表示氢原子、卤原子、低碳基、低烷氧基、低烷硫基、低烷氧基取代的（低碳基）基团、低烷氧基取代的（低烷氧基）基团、低烷氧基（低烷氧基）取代的（低碳基）基团、环状低碳基、卤（低碳基）基团或由通式HO-A-表示的基团，其中A表示低碳亚基、低碳亚氧基或低碳硫基；R2表示氢原子、卤原子、低碳基、环状低碳基、低烷氧基、氨基、（低酰基）氨基、单（低碳基）氨基或双（低碳基）氨基；R3表示氢原子或低碳基，或其药学上可接受的盐，或其前药，其用作预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症的药剂，以及包含它们的制药组合物和制药用途和中间体。
• NITROGENOUS HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE THEREFOR
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1405859A1

  公开（公告）日：2004-04-07

  The present invention is to provide a nitrogen-containing heterocyclic derivative represented by the general formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof, which exerts an excellent inhibitory activity in human SGLT2 and is useful as an agent for the prevention or treatment of a disease associated with hyperglycemia such as diabetes etc., or a pharmaceutical composition comprising the same and a pharmaceutical use thereof and a production intermediate thereof. In the general formula (I), X1 and X3 are N or CH; X2 is N or CR2; X4 is N or CR3; and with the proviso that one or two of X1, X2, X3 and X4 are N; and R1, R2 and R3 are a hydrogen atom etc.

  本发明旨在提供一种由通式(I)代表的含氮杂环衍生物或其药学上可接受的盐，或其原药，该衍生物对人SGLT2具有优异的抑制活性，可作为预防或治疗糖尿病等与高血糖相关疾病的药物，或由其组成的药物组合物及其药物用途和其生产中间体。在通式（I）中，X1 和 X3 是 N 或 CH；X2 是 N 或 CR2；X4 是 N 或 CR3；但条件是 X1、X2、X3 和 X4 中的一个或两个是 N；R1、R2 和 R3 是氢原子等。
• US7271153B2
  申请人：——

  公开号：US7271153B2

  公开（公告）日：2007-09-18